Cosmos Health (NASDAQ:COSM) & BeOne Medicines (NASDAQ:ONC) Head-To-Head Analysis

BeOne Medicines (NASDAQ:ONC) and Cosmos Health (NASDAQ:COSM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Earnings & Valuation

This table compares BeOne Medicines and Cosmos Health”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$3.81 billion	9.77	-$644.79 million	$0.51	665.33
Cosmos Health	$54.43 million	0.34	-$16.18 million	($0.75)	-0.66

Cosmos Health has lower revenue, but higher earnings than BeOne Medicines. Cosmos Health is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BeOne Medicines and Cosmos Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	1.38%	5.52%	3.17%
Cosmos Health	-31.01%	-33.19%	-13.65%

Insider & Institutional Ownership

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 12.6% of Cosmos Health shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by insiders. Comparatively, 25.1% of Cosmos Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility & Risk

BeOne Medicines has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Cosmos Health has a beta of 5.37, meaning that its share price is 437% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for BeOne Medicines and Cosmos Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1	1	13	0	2.80
Cosmos Health	1	0	0	0	1.00

BeOne Medicines presently has a consensus target price of $378.43, indicating a potential upside of 11.53%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, research analysts clearly believe BeOne Medicines is more favorable than Cosmos Health.

Summary

BeOne Medicines beats Cosmos Health on 11 of the 14 factors compared between the two stocks.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

About Cosmos Health

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.